Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Sarcopenia Treatment Market Size Forecast: How Large Could The Market Become By 2030?
The market for sarcopenia treatments has experienced robust expansion lately, projected to increase from approximately $3.72 billion in 2025 to $3.94 billion in 2026, representing a compound annual growth rate (CAGR) of 5.9 percent. This surge during the past period is a result of several factors, including a burgeoning demographic of older individuals, heightened consciousness regarding muscle deterioration associated with aging, a reliance on established strategies like physical therapy and dietary supplementation, the scarcity of sanctioned pharmacological interventions, and an uptick in disorders affecting mobility.
The market for sarcopenia treatments is projected to experience robust expansion, reaching an estimated $4.97 billion by 2030 and exhibiting a compound annual growth rate of 6.0% over the coming years. This anticipated growth trajectory is propelled by several key factors, including the ongoing development of innovative pharmacological therapies, a heightened emphasis on early detection and proactive management strategies, increased healthcare investments in the care of the elderly, the escalating incidence of chronic conditions that impact muscle vitality, and a growing number of clinical investigations focused on muscle regeneration. During this forecast period, significant trends are expected to shape the market, such as a greater integration of combined pharmaceutical and exercise-based therapeutic approaches, a noticeable rise in the utilization of nutritional supplements for sarcopenia control, intensified clinical research into myostatin inhibitors and anabolic agents, a growing recognition and diagnosis of sarcopenia among older demographic segments, and a more widespread incorporation of physical therapy within established treatment protocols.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp
Sarcopenia Treatment Market Growth Momentum: Which Factors Are Influencing Demand?
A surge in malnutrition is anticipated to be a key driver for the expansion of the sarcopenia treatment market in the future. Malnutrition is characterized by insufficient, excessive, or imbalanced consumption of energy and nutrients, encompassing conditions ranging from undernutrition to being overweight, obese, or developing noncommunicable diseases linked to diet. Treatments for sarcopenia are designed to tackle the concurrent issues of malnutrition and sarcopenia prevalent in elderly individuals, employing strategies like dietary interventions and physical activity to enhance muscle mass, strength, and general nutritional well-being. A compelling example of this trend is the data from January 2025, where the United States Department of Agriculture indicated that 17.9% of households with children experienced food insecurity in 2023, affecting approximately 6.5 million families. Consequently, the increasing prevalence of malnutrition is directly contributing to the growth trajectory of the sarcopenia treatment market.
Sarcopenia Treatment Market Categorization By Product Type And Application
The sarcopenia treatment market covered in this report is segmented –
1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types
2) By Type: Primary Sarcopenia, Secondary Sarcopenia
3) By Route Of Administration: Oral, Parenteral, Enteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein
2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin
3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate
4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions
Sarcopenia Treatment Market Trends Reshaping Industry Growth
Leading pharmaceutical and biotechnology firms in the sarcopenia treatment sector are intensifying their efforts to develop and investigate a range of innovative therapeutic approaches to enhance patient care. The underlying purpose of a clinical study involves a disciplined inquiry using human participants to rigorously assess the safety, effectiveness, and ultimate results of a medical intervention. A compelling example of this commitment is the September 2023 announcement from Biophytis, a French life sciences enterprise, regarding its receipt of Food and Drug Administration (FDA) approval to commence the SARA-31 Phase 3 investigation for sarcopenia. This particular trial is designed to scrutinize the therapeutic value and safety profile of Sarconeos (BIO101) when administered to individuals diagnosed with sarcopenia who exhibit a heightened susceptibility to motor function impairment. This initiative represents a substantial leap forward in both technological innovation and pharmaceutical treatment strategies, presenting potential advantages in efficacy and safety for those afflicted with severe forms of sarcopenia, and notably, stands as the inaugural phase 3 trial in this specific disease area to gain FDA clearance. The investigation is projected to enroll approximately 900 participants, all exceeding 65 years of age and exhibiting characteristics of sarcopenia, such as diminished walking velocity and reduced handgrip strength. Key metrics for measuring success, serving as primary endpoints, will encompass the evaluation of major mobility disability (MMD) risk, walking speed, handgrip strength, and the subjective experience of patient-reported quality of life.
Sarcopenia Treatment Market Company Landscape And Strategic Competition
Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill
Access The Complete Sarcopenia Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report
Sarcopenia Treatment Market Regional Analysis And Leading Geography
North Americawas the largest region in the sarcopenia treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
